Plasma and platelet taurine are reduced in subjects with insulin-dependent diabetes mellitus: effects of taurine supplementation (original) (raw)
Related papers
Taurine in Lower Concentration Attenuates Platelet Activity
Food and Public Health, 2012
Taurine, 2-aminoethanesulphonic acid is a common ingredient of energy drinks which is very popular with young adults. Taurine in energy drinks is known to enhance muscular performance in athletes. However, caffeine in high concentrations as found in most energy drinks have also been implicated to play an adverse role leading to cardiovascular diseases (CVD). Hyper activation of platelets is one of the major risk factors of CVD. The aim of the study was to evaluate effect of taurine alone on platelet aggregation and activation of platelet surface antigens by flowcytometry. It is hypothesized that taurine's antioxidant property would inhibit platelet activity. Twelve healthy, male and female, volunteers aged 20-60 years were recruited for this study. A statistically significant inhibition of platelet aggregation was observed upon stimulation with agonists adenosine diphosphate (ADP), collagen and arachidonic acid (AA) (p<0.05). The platelet surface expression of PAC1 and p-selectin induced by all three agonists also decreased compared to baseline but was not statistically significant. In conclusion this study demonstrated that taurine at a concentration of 500µM (energy drinks contain approximately 31mM taurine), inhibits the platelet hyperactivity in platelet rich plasma. Further mechanistic and interventional studies are required to examine the pathway involved in support of beneficial role of taurine in prevention of risk factors leading to cardiovascular disorders. Synergistic effect of varying doses of caffeine and taurine will also be evaluated to obtain most effective and protective doses for energy drinks.
Biomolecules, 2019
Background: Taurine has an active role in providing glucose homeostasis and diabetes causes a decline in taurine levels. This paper investigates the relationship between taurine and diabetic complications, patients’ demographic features, and biochemical parameters. Methods: Fifty-nine patients with type 2 diabetes mellitus (T2DM), and 28 healthy control subjects between the ages of 32 and 82 were included in the study. The mean age of subjects was 55.6 ± 10.3 and mean diabetes duration was 10.2 ± 6.0 years. The most commonly accompanying comorbidity was hypertension (HT) (64.5%, n = 38), and the most frequent diabetic complication was neuropathy (50.8%, n = 30). Plasma taurine concentrations were measured by an enzyme-linked immunoassay (ELISA) kit. Results: Plasma taurine concentrations were significantly lower in diabetic patients (0.6 ± 0.1 mmol/L) than controls (0.8 ± 0.2 mmol/L) and in hypertensive (0. 6 ± 0.1 mmol/L) patients (p = 0.000, p = 0.027 respectively). Conclusion: Pl...
Increased arachidonic acid uptake by platelets from insulin-dependent diabetics and diabetic rats
Diabetes Research and Clinical Practice, 1989
14C-Arachidonic acid uptake was measured in platelets obtained from 15 insulin-dependent diabetic and 17 control subjects and in 12 streptozotocin-diabetic and 21 control rats. The 14C-arachidonic acid uptake, expressed as pmol/lO' platelets/min, mean + SEM, was significantly higher in platelets from diabetic subjects (2.80 k 0.23) and diabetic rats (1.73 f 0.20) than in the control subjects (2.29 f 0.15) and the control rats (1.35 + 0.08). No significant correlations were found between arachidonic acid uptake and glucose, total cholesterol or triglyceride plasma levels in either rats or humans. Arachidonic acid uptake was inhibited by indometacin but not by nordihydroguaiaretic acid, in diabetic as well as in control subjects. The present results suggest that the increased arachidonic acid uptake by platelets from insulin-dependent diabetic patients and streptozotocin-diabetic rats depends on their increased platelet arachidonic acid utilization through the cyclooxygenase pathway.
Neurochemical Research, 2004
Taurine is a semiessential amino acid, and its deficiency is involved in retinal and cardiac degenerations. In recent years, it was found that diabetes mellitus (DM) is associated with taurine, and many in vivo experimental studies showed that taurine administration is able to reduce the alterations induced by DM in the retina, lens, and peripheral nerve, although its effects on diabetic kidney are dubious. Interestingly, long-term taurine supplementation reduces the mortality rate in diabetic rats. The mechanisms by which taurine exerts beneficial effects in DM are discussed below. Recently, it has been suggested that taurine deficiency may alter the endocrine pancreas "fetal programming," increasing the risk of insulin resistance in adult life. The bulk of experimental data suggests that taurine administration could be useful in the treatment of type 1 DM and in the prevention of insulin resistance. KEY WORDS: Taurine; diabetes mellitus; oxidative stress; insulin resistance. renal and hepatic mechanisms that permit the conservation 0364-3190/04/0100-0143/0
Diabetology & Metabolic Syndrome
Background Reduced serum level of taurine in type 2 diabetes mellitus (T2DM) was shown to be associated with the metabolic alterations and clinical complications of diabetes. Dietary supplementation with taurine may attenuate oxidative stress and inflammatory responses in T2DM as well as alleviate diabetes-induced complications. Hence, this study evaluated the effect of taurine supplementation on oxidative stress and inflammatory biomarkers in patients with T2DM. Methods Fifty patients with T2DM were randomly allocated to two groups to consume either taurine (containing 1000 mg taurine), or placebo (containing crystalline microcellulose) three times per day for 8 weeks. Anthropometric data, dietary intake, serum total antioxidant capacity (TAC), malondialdehyde (MDA), the activities of antioxidant enzymes superoxide dismutase (SOD) and catalase (CAT), serum levels of tumor necrosis factor alpha (TNF-α), interleukin 6 (IL-6) and high-sensitivity C-reactive protein (hs-CRP) were asses...
European Journal of Clinical Nutrition, 2004
Background: The prevalence of type 2 diabetes mellitus (T2DM) is increasing with an epidemic growth rate. Animal studies with taurine supplementation have shown increased insulin secretion and action, suggesting that taurine supplementation may have a potential to prevent T2DM. Objective: To assess the effect of taurine treatment on insulin secretion and action, and on plasma lipid levels in overweight men with a positive history of T2DM. Design: 20 nondiabetic subjects were included in a double-blinded, randomized, crossover study, receiving a daily supplementation of 1.5 g taurine or placebo for two periods of 8 weeks. The subjects were overweight first-degree relatives of T2DM patients. An intravenous glucose tolerance test (IVGTT) was used to measure first-phase insulin secretory response, and a euglycemic hyperinsulinemic clamp was used to determine peripheral insulin action. Results: Mean plasma taurine concentration was 3977 (s.d.) mmol/l after placebo and 131762 mmol/l after taurine intervention (Po0.0001). There was no significant difference after taurine intervention compared to placebo in incremental insulin response (Ins incr. ) neither during the IVGTT, nor in insulin-stimulated glucose disposal during the clamp. Insulin secretion, adjusted for insulin sensitivity, was also unchanged. There was no significant effect of taurine supplementation on blood lipid levels as well. Conclusion: Daily supplementation with 1.5 g taurine for 8 weeks had no effect on insulin secretion or sensitivity, or on blood lipid levels. These findings in persons with an increased risk of T2DM are in contrast to those from animal studies, and do not support the assumption that dietary supplementation with taurine can be used to prevent the development of T2DM.
Altered platelet functions in non-insulin-dependent diabetes mellitus (NIDDM)
Thrombosis Research, 1994
We have studied platelet aggregation and membrane fluidity, along with various biochemical parameters, in 19 non-insulin-dependent diabetes mellitus (NIDDM) patients prior to control of blood sugar, 11 patients after control of blood sugar, and 26 normal subjects. Platelet cholestrol: phospholipid ratio and basal levels of ) [Ca+]were comparable between normal and uncontrolled NIDDM. Basal levels of malonaldehyde (MDA) and the levels of [Ca++], as well as MDA after the addition of arachidonic acid, were 2.5-fold, 5-fold, and 2.5-fold higher, respectively, in the uncontrolled NIDDM group than normals. Platelet aggregation in response to ADP (0.25 uM), epinephrine (1.25 uM), and arachidonic acid (0.25 mM) was significantly higher in uncontrolled NIDDM than in normals (75%, 40% and 52%, respectively). Platelet fluorescence polarization was also higher in NIDDM patients indicating decreased membrane fluidity in such patients as compared to normals. After control of blood sugar in 11 NIDDM patients, agonist-stimulated platelet aggregation and other biochemical parameters were comparable to normals.
Pharmaceutical Sciences
Background: Prevention and management of type 2 diabetes mellitus (T2DM), as a major, noncommunicable disease with increasing prevalence, is one of the major human challenges. The aim of this systematic review is to summarize current studies about the potential roles of taurine in T2DM, to identify knowledge gaps and to provide recommendations for the way forward. Methods: The literature search was performed in PubMed, SCOPUS, Embase, ProQuest and Google Scholar electronic databases to December 2019. All studies investigating the impacts of taurine in T2DM which met the inclusion criteria were eligible. Results: Out of 1381 articles found in the search, 12 were included. Findings of taurine supplementation on glycemic control in T2DM showed improving effect of taurine on fasting and postprandial blood glucose, serum insulin level, insulin resistance, function of beta cells, and insulin sensitivity. But, the results for Hemoglobin A1c and homeostatic model assessmentinsulin resistance (HOMA-IR) were contradictory. Also, taurine reduced total cholesterol, TG, and low density lipoprotein-cholesterol (LDL-C) levels, however, the evidence on high density lipoprotein-cholesterol (HDL-C) was insufficient. Findings didn not support antioxidative role of taurine in T2DM. Conclusion: As a whole, taurine has potential to improve glycemic status and dyslipidemia. However, more clinical trials are needed to explore precise mechanisms underlying taurine on metabolic variables, oxidative stress, and inflammatory biomarkers, according to the recommendations for future directions.
Effects of taurine in glucose and taurine administration
Taurine has several biological processes such as hypoglycemic action, antioxidation, detoxification, etc. To assess the effect of taurine administration on the guinea pigs with hyperglycemia, blood glucose, Cpeptide levels together with morphologic alterations in the pancreatic ultrastructure were investigated in terms of hypoglycemic action and malondialdehyde and total sulfhydryl group levels with regard to oxidation-antioxidation relation. Animals were divided into four groups of six. Glucose supplementation group was administrated a single dose of glucose (400 mg=kg, i.p.) injection. Glucose and taurine supplementation group was administrated glucose treatment (a single dose, 400 mg=kg, i.p.) following taurine (a single dose, 200 mg=kg, i.p.). Taurine and glucose supplementation group was administered taurine treatment (a single dose, 200 mg=kg, i.p.) following glucose treatment (a single dose, 400 mg=kg, i.p.). Control animals received no treatment. Blood samples were collected at the end of the experiments for the determination of glucose, C-peptide (indicator of insulin secretion), lipid peroxidation (thiobarbituric acid reactive substances), and total sulfhydryl groups levels. Pancreatic tissue samples were then collected and processed for transmission electron microscopy. The findings showed that glucose supplementation following taurine administration significantly decreased blood glucose level by increasing C-peptide level and the pancreatic secretion stimulated morphologically and insignificantly changed thiobarbituric acid reactive substances and total sulfhydryl group levels. These observations suggest that taurine administration may be useful in hyperglycemia because of its hypoglycemic and protective effects.